132 related articles for article (PubMed ID: 38269512)
1. Durvalumab and taxane family combination therapy enhances the antitumoral effects for NSCLC: An in vitro study.
Firoozi MR; Sadeghi-Mohammadi S; Asadi M; Shekari N; Seyed Nejad F; Alizade-Harakiyan M; Soleimani Z; Zarredar H
Cell Biochem Funct; 2024 Jan; 42(1):e3919. PubMed ID: 38269512
[TBL] [Abstract][Full Text] [Related]
2. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
3. Emodin enhances antitumor effect of paclitaxel on human non-small-cell lung cancer cells in vitro and in vivo.
Chen S; Zhang Z; Zhang J
Drug Des Devel Ther; 2019; 13():1145-1153. PubMed ID: 31114158
[No Abstract] [Full Text] [Related]
4. Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.
Hu R; Li T; Hui K; Chen Z; Wang N; Wu X; Ge L; Zhou L
Mol Med Rep; 2020 Nov; 22(5):3935-3943. PubMed ID: 32901884
[TBL] [Abstract][Full Text] [Related]
5. Multi-CpG linear regression models to accurately predict paclitaxel and docetaxel activity in cancer cell lines.
Bacolod MD; Fisher PB; Barany F
Adv Cancer Res; 2023; 158():233-292. PubMed ID: 36990534
[TBL] [Abstract][Full Text] [Related]
6. Synergistic anticancer effects of andrographolide and paclitaxel against A549 NSCLC cells.
Yuan H; Sun B; Gao F; Lan M
Pharm Biol; 2016 Nov; 54(11):2629-2635. PubMed ID: 27159496
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Anticancer Activity of Combined Use of Caffeic Acid with Paclitaxel Enhances Apoptosis of Non-Small-Cell Lung Cancer H1299 Cells in Vivo and in Vitro.
Min J; Shen H; Xi W; Wang Q; Yin L; Zhang Y; Yu Y; Yang Q; Wang ZN
Cell Physiol Biochem; 2018; 48(4):1433-1442. PubMed ID: 30064123
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Anti-Metastatic Potential of the Combination of Fisetin with Paclitaxel on A549 Non-Small Cell Lung Cancer Cells.
Klimaszewska-Wiśniewska A; Hałas-Wiśniewska M; Grzanka A; Grzanka D
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495431
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.
Garassino MC; Cho BC; Kim JH; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray JE; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo RA; Huang Y; Wadsworth C; Dennis PA; Rizvi NA;
Lancet Oncol; 2018 Apr; 19(4):521-536. PubMed ID: 29545095
[TBL] [Abstract][Full Text] [Related]
10. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo.
Sampath D; Discafani CM; Loganzo F; Beyer C; Liu H; Tan X; Musto S; Annable T; Gallagher P; Rios C; Greenberger LM
Mol Cancer Ther; 2003 Sep; 2(9):873-84. PubMed ID: 14555706
[TBL] [Abstract][Full Text] [Related]
11. Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1/PD-L1 treatment.
Tozuka T; Kitazono S; Sakamoto H; Yoshida H; Amino Y; Uematsu S; Yoshizawa T; Hasegawa T; Ariyasu R; Uchibori K; Yanagitani N; Horai T; Seike M; Gemma A; Nishio M
Lung Cancer; 2020 Jun; 144():71-75. PubMed ID: 32387683
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Antitumor Activity of SH003 and Docetaxel via EGFR Signaling Inhibition in Non-Small Cell Lung Cancer.
Jeong MS; Lee KW; Choi YJ; Kim YG; Hwang HH; Lee SY; Jung SE; Park SA; Lee JH; Joo YJ; Cho SG; Ko SG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445110
[TBL] [Abstract][Full Text] [Related]
13. Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Melosky B; Juergens R; Hirsh V; McLeod D; Leighl N; Tsao MS; Card PB; Chu Q
Oncologist; 2020 Jan; 25(1):64-77. PubMed ID: 31138727
[TBL] [Abstract][Full Text] [Related]
14. Chrysin Increases the Therapeutic Efficacy of Docetaxel and Mitigates Docetaxel-Induced Edema.
Lim HK; Kim KM; Jeong SY; Choi EK; Jung J
Integr Cancer Ther; 2017 Dec; 16(4):496-504. PubMed ID: 27151585
[TBL] [Abstract][Full Text] [Related]
15. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer.
Kehl KL; Greenwald S; Chamoun NG; Manberg PJ; Schrag D
JAMA Netw Open; 2021 May; 4(5):e2111113. PubMed ID: 34019086
[TBL] [Abstract][Full Text] [Related]
16. Hsa_circ_0092887 targeting miR-490-5p/UBE2T promotes paclitaxel resistance in non-small cell lung cancer.
Wang L; Zhang Z; Tian H
J Clin Lab Anal; 2023 Jan; 37(1):e24781. PubMed ID: 36550019
[TBL] [Abstract][Full Text] [Related]
17. Durvalumab for the treatment of non-small cell lung cancer.
Murakami S
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1009-1016. PubMed ID: 31782989
[No Abstract] [Full Text] [Related]
18. Taxanes for advanced non-small cell lung cancer.
Ramalingam S; Belani CP
Expert Opin Pharmacother; 2002 Dec; 3(12):1693-709. PubMed ID: 12472367
[TBL] [Abstract][Full Text] [Related]
19. Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy.
Yonekura S; Endo Y; Fujii H; Ishikawa M; Egawa G; Kabashima K
J Dermatol; 2023 Nov; 50(11):1493-1496. PubMed ID: 37400887
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel.
Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP
Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
